Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 20/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 17/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.39 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894988 | 0.94 | HDAC3 (0.41) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| Trifluoroacetic Acid SCHEMBL9895577 | 0.73 | HDAC1 (0.35) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL7899161 | 0.73 | HDAC3 (0.42) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| Trifluoroacetic Acid SCHEMBL9895341 | 0.71 | HDAC3 (0.41) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| Trifluoroacetic Acid SCHEMBL9895346 | 0.71 | HDAC3 (0.41) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| Trifluoroacetic Acid SCHEMBL9894994 | 0.67 | HDAC3 (0.38) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| Trifluoroacetic Acid SCHEMBL9894997 | 0.67 | HDAC3 (0.38) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL9895345 | 0.67 | HDAC3 (0.37) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL9895336 | 0.66 | CYP19A1 (0.37) | HDAC3HDAC1HDAC8HDAC4HDAC6 | |
| SCHEMBL7898598 | 0.66 | CYP19A1 (0.37) | HDAC3HDAC1HDAC8HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155439-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | MERIAL, INC. | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149750-A1 | ARYLOAZOL-2-YL CYANOETHYLAMINO COMPOUNDS, METHOD OF MAKING AND METHOD OF USING THEREOF | CYP4X1, CBR3, TYR | HDAC3 210/4885HDAC1 1380/4885HDAC8 2259/4885 |
| US-20140155439-A1 | ENZYME INHIBITORS | HDAC4, HDAC1, HDAC3 | HDAC3 3/4885HDAC1 2/4885HDAC8 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.